Clinical trials · New York
Lymphoma clinical trials in New York
We’re tracking 176 recruiting lymphoma studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Albany, New YorkAges 18 years+ - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
New York, New YorkAges 18 years+ - NCT07691606RecruitingPhase 1
Testing a new drug for B-cell lymphoma that has come back
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
New York, New YorkAges 18 years+ - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Buffalo, New YorkAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
New York, New YorkAges 18 years+ - NCT04301076RecruitingPhase 1
Testing lenalidomide with EPOCH for adult T-cell leukemia-lymphoma
This trial tests whether adding lenalidomide to a standard chemotherapy regimen (EPOCH) helps people with adult T-cell leukemia-lymphoma (ATLL). It aims to improve how well the treatment works.
Commack, New YorkAges 18 years+ - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Albany, New YorkAges 12 months–25 years - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
New York, New YorkAges 18–80 - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
New York, New YorkAges Up to 25 years - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
New York, New YorkAges 18 years+ - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Albany, New YorkAges Up to 22 years - NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
New York, New YorkAges 18 years+ - NCT04806295Recruiting
National registry for people with blood cancers
This is a national research registry that collects information from people with blood cancer before, during, and after treatment. It may help researchers better understand care and outcomes and may connect you to future studies.
Rye Brook, New YorkAges 21 years+ - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Rochester, New YorkAges 18 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05296304RecruitingPhase 1
Bexarotene plus radiation for mycosis fungoides skin lymphoma
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
Commack, New YorkAges 18 years+ - NCT05643235Recruiting
Loop monitor to watch heart rhythms when starting a BTK inhibitor
This study checks how often abnormal heart rhythms happen when you start a BTK inhibitor (used for certain blood cancers). It uses a small implanted heart monitor to record your rhythm continuously before and after starting the medication, so doctors can detect and manage problems early.
New Hyde Park, New YorkAges 18 years+ - NCT05680558RecruitingPhase 2
Photopheresis for early skin lymphoma in adults
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
New York, New YorkAges 18 years+ - NCT05884333RecruitingPhase 2
Cord blood transplant for adults with blood cancer
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
New York, New YorkAges 21–65 - NCT06418204Recruiting
Cannabis use study for cancer patients in community clinics
This study looks at the benefits and risks of using cannabis or cannabinoids for cancer patients. It aims to help understand how these products affect symptoms and quality of life during chemotherapy or immunotherapy.
Jamaica, New YorkAges 18 years+ - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT06698003RecruitingPhase 2
Mogamulizumab to Prevent Leukemia in HTLV-1 Carriers
This trial tests whether a drug called mogamulizumab can prevent adult T-cell leukemia/lymphoma in people who carry the HTLV-1 virus and have a high viral load. It is for patients who have not yet developed the blood cancer.
Commack, New YorkAges 18 years+ - NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
New York, New YorkAges 18 years+
Lymphoma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting lymphoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- Columbia University Irving Medical Center · 6 studies
- NYU Langone Health · 5 studies
- Memorial Sloan Kettering Commack · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Montefiore Medical Center · 3 studies
- NYU Langone Hospital - Long Island · 3 studies
- University of Rochester · 3 studies
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lymphoma trials in other states
Common questions
- Are there lymphoma clinical trials in New York?
- Yes. We're currently tracking 176 recruiting lymphoma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.